Advancements in folate receptor targeting for anti-cancer therapy: A small molecule-drug conjugate approach

Bioorg Chem. 2021 Apr 27;112:104946. doi: 10.1016/j.bioorg.2021.104946. Online ahead of print.ABSTRACTTargeted delivery combined with controlled release of drugs has a crucial role in future of personalized medicine. The majority of cancer drugs are intended to interfere with one or more cellular events. Anticancer agents can also be toxic to healthy cells, as healthy cells may also need to proliferate and avoid apoptosis. The focus of this review covers the principles, advantages, drawbacks and summarize criteria that must be met for design of small molecule-drug conjugates (SMDCs) to achieve the desired therapeutic potency with minimal toxicity. SMDCs are composed of a targeting ligand, a releasable bridge, a spacer, and a therapeutic payload. We summarize the criteria for the effective design that influences the selection of tumor specific receptor and optimum elements in the design of SMDCs. We also discuss the criteria for selecting the optimal therapeutic drug payload, spacer and linker. The linker chemistries and cleavage strategies are also discussed. Finally, we review the folate receptor targeting SMDCs that are in preclinical development and in clinical trials.PMID:33989916 | DOI:10.1016/j.bioorg.2021.104946
Source: Bioorganic Chemistry - Category: Chemistry Authors: Source Type: research